RecruitingPhase 3ACTRN12621001238864

PEAChY-M Pharmacological Emergency management of Agitation in Children and Young people: a randomised controlled trial of intraMuscular medication

PEAChY-M Pharmacological Emergency management of Agitation in Children and Young people: a randomised controlled trial of the effectiveness of intraMuscular (IM) medication for the management of acute severe behavioural disturbance.


Sponsor

Murdoch Children's Research Institute (MCRI)

Enrollment

348 participants

Start Date

Oct 25, 2021

Study Type

Interventional

Conditions

Summary

Acute severe behavioural disturbance (ASBD) is an emergency situation where a patient experiences severe agitation or aggression. One of the common strategies used to manage those presenting to the emergency department (ED) with ASBD is the provision of medications. Medications assist in allowing the young person to gain control over their behaviour. In most instances, oral medications are used. For a small proportion of young people with ASBD, their emotional dysregulation is so extreme that they are unable or unwilling to accept oral medication and, therefore, IM medication is required to de-escalate their behaviour. In individuals less than 18 years of age, there is no evidence available to guide doctors about which medications are the most effective, despite them being commonly used to manage ASBD. It is also not known how well these medications are tolerated by young people. Therefore, the primary aim of this study is to determine whether, in children and adolescents with ASBD, IM olanzapine is more effective than IM droperidol at achieving successful sedation (i.e.: a state of calm) at 1 hour after randomisation. These medications were chosen as they are the two of the most commonly used medications in Australia. This study will be a randomised, open label, multi-centre effectiveness trial which will enrol young people aged 9 to 17 and 364 days presenting to participating EDs with ASBD. We hope to determine which medication is most effective and to assess the side effects of these medications. We hypothesise that 15% more children will achieve successful sedation 1 hour after randomisation to olanzapine compared to those children who were randomised to droperidol.


Eligibility

Sex: Both males and femalesMin Age: 9 YearssMax Age: 17 Yearss

Plain Language Summary

Simplified for easier understanding

This study is focused on children and young people aged 9–17 who arrive at the Emergency Department in a state of severe agitation or aggression — a situation doctors call acute severe behavioural disturbance (ASBD). When non-medication approaches have not worked and the young person's safety is at risk, doctors may need to administer medication by injection. Two medications are currently used most often in Australia for this purpose: olanzapine and droperidol. However, there is very little evidence about which works better or is better tolerated in young people. This randomised trial is comparing the two medications to see which one more effectively achieves a calm and safe state within one hour of being given. This could help emergency doctors make better treatment decisions and improve the care of distressed young people. This trial is conducted in Emergency Departments and applies to children aged 9 to 17 who are already being assessed and treated by ED clinicians for severe behavioural disturbance. Families and carers of patients are involved in the consent process. Children who have known allergies to either medication, or who have certain heart conditions (like long QT syndrome), are not eligible.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PEAChY-M is a randomised controlled trial which will compare the effectiveness of intramuscular (IM) olanzapine [arm one] to IM droperidol [arm two] for the management of paediatric acute severe behav

PEAChY-M is a randomised controlled trial which will compare the effectiveness of intramuscular (IM) olanzapine [arm one] to IM droperidol [arm two] for the management of paediatric acute severe behavioural disturbance occurring in the emergency department (ED). ASBD will be determined by confirming the participant has a Sedation Assessment Tool (SAT) score of +1 or greater. Dosing will be based on weight. This is an open label study. The trial medication will be provided by the clinical staff caring for the participant in the ED. Only one dose will be provided as part of the PEAChY-M study. No modifications to the doses or the medications provided will be allowed. Arm One: Participants will receive 5mg IM olanzapine if they weigh <40kg or 10mg if they weigh 40kg or greater.


Locations(10)

The Royal Childrens Hospital - Parkville

NSW,QLD,SA,WA,VIC, Australia

Monash Children’s Hospital - Clayton

NSW,QLD,SA,WA,VIC, Australia

Perth Children's Hospital - Nedlands

NSW,QLD,SA,WA,VIC, Australia

Womens and Childrens Hospital - North Adelaide

NSW,QLD,SA,WA,VIC, Australia

Gold Coast University Hospital - Southport

NSW,QLD,SA,WA,VIC, Australia

Queensland Children's Hospital - South Brisbane

NSW,QLD,SA,WA,VIC, Australia

The Children's Hospital at Westmead - Westmead

NSW,QLD,SA,WA,VIC, Australia

Ballarat Health Services (Base Hospital) - Ballarat Central

NSW,QLD,SA,WA,VIC, Australia

Sunshine Hospital - St Albans

NSW,QLD,SA,WA,VIC, Australia

Sunshine Coast University Hospital - Birtinya

NSW,QLD,SA,WA,VIC, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12621001238864